Proactive Investors - Run By Investors For Investors

VentriPoint Diagnostics receives order for its VMS Plus - from leading cardiac hospital in Toronto

The VMS+ system uses standard 2D echocardiogram images and Artificial Intelligence (AI)
VentriPoint Diagnostics receives order for its VMS Plus - from leading cardiac hospital in Toronto
Pictured - major heart surgery

VentriPoint Diagnostics Ltd (CVE:VPT) and its heart analysis technology was boosted again today - as St. Michael's Hospital in Toronto, Canada ordered its VMS Plus system to use it to assess cardiac patients.

The VMS+ system uses standard 2D echocardiogram images and Artificial Intelligence (AI) to show 3D volumes for, significantly, all four chambers of the heart.

READ: VentriPoint Diagnostics reveals that University of Chicago will assess its heart analysis system

This provides medics with a more efficient and cost-effective method for evaluating cardiac volumes and ejection fractions.

The heart is a pump, so when there is a problem, it is not always easy to know where exactly the fault lies, so analysis of each of the four chambers is essential.

Dr Howard Leong-Poi and Dr Chi-Ming Chow are spearheading the VMS+ acquisition.

Leong-Poi is the head of the cardiology division at St. Michael's Hospital and a clinician-scientist in the Keenan Research Centre for biomedical science.

Chow, meanwhile, is the director of the echocardiography lab and has expertise in the development of innovative technologies in the practice of echocardiography.

"We are very pleased to have the interest and commitment from such a high profile cardiac institution in our own backyard," said Desmond Hirson, the president of VentriPoint.

"We believe that our AI technology and product in the hands of Drs. Leong-Poi and Chow will make a valuable difference to patient outcomes."

READ: VentriPoint Diagnostics shares tick higher as it hires new marketing manager

Dr Leong-Poi added: "Artificial intelligence holds a great deal of promise for many clinical imaging applications and we are very excited to participate with this leading-edge technology to more accurately assess cardiac chamber volumes and function by echocardiography."

VentriPoint noted that there were many potential applications for this innovative technology - including assessing ventricular volumes and function after percutaneous valve interventions, and after cancer chemotherapies.

The firm's VMS system is getting some traction at the moment. Last week, it told investors that the University of Chicago's medical centre was to assess the system.

With the recent market clearance from the key FDA, Chicago will be one of the first sites to evaluate and publish on the performance of the VMS+ system compared to MRI for all four cardiac chambers, spearheaded by Dr Roberto Lang, said the company.

Shares in the company pumped up over 21% to $0.20 in Toronto.

Reporting by Giles Gwinnett

[email protected]

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use